Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
Katoh N, Tanaka A, Takahashi H, et al. Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J). Curr Med Res Opin. 2025 Jan;41(1):1-12. doi:10.1080/03007995.2024.2436982. Epub 2024 Dec 13. | PMID:
Phase 3, double-blind, placebo-controlled, randomized clinical trial
Japanese patients with moderate-to-severe atopic dermatitis
Lebrikizumab combined with topical corticosteroids
Not explicitly stated
This phase 3, double-blind, placebo-controlled, randomized clinical trial evaluated the efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients suffering from moderate-to-severe atopic dermatitis.
Key Learning Points
-
•
Lebrikizumab combined with topical corticosteroids significantly improved symptoms in Japanese patients with moderate-to-severe atopic dermatitis. -
•
The combination demonstrated a favorable safety profile with manageable adverse events.
Read Full Study Review
Take Assessment Quiz
🎧 AI Audio Overview
